Wegovy® Pill Results: What to Expect From the New Oral Tablet


Curious about Wegovy® pill results? Learn how the oral Wegovy® tablet works and whether it could be a good fit for your health goals.
- Interested in learning about Wegovy® pill results? This oral form was approved by the FDA in December 2025 and became the first oral GLP-1 medication for weight management.
- In clinical trials, participants taking the Wegovy® tablet experienced significant weight loss over 64 weeks, with results varying by individual.
- The pill must be taken every morning on an empty stomach with no more than four ounces of water, followed by a 30-minute wait before eating or drinking.
- Common side effects, such as nausea and digestive discomfort, are most noticeable during dose escalation and tend to improve over time.
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new medication.

For many people interested in GLP-1 medications, the idea of a weekly injection may feel like a dealbreaker, especially if needles make you a little squeamish. In early 2026, however, the Wegovy® pill became available (by prescription) at pharmacies across the country.
But how well does it actually work? And what should you realistically expect if you start taking it?
Here’s a closer look at Wegovy® pill results, how the tablet compares to the injectable version, and what to keep in mind when taking Wegovy® in any form.
What Is the Wegovy® Pill?
The Wegovy® pill is a once-daily oral tablet that belongs to the GLP-1 receptor agonist class. It was approved by the FDA in December 2025 and launched in January 2026, making it the first oral GLP-1 receptor agonist approved specifically for weight management.
Like the injection, the Wegovy® tablet is approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. It’s also approved to reduce the risk of major cardiovascular events in adults with established heart disease.
Interestingly, the Wegovy® pill uses an absorption enhancer called SNAC (Salcaprozate sodium). Because semaglutide wouldn’t survive the digestive process on its own, SNAC protects it from stomach acid and helps it reach the bloodstream. This is also why the dosing instructions are so specific (more on this below).
How Does the Wegovy® Tablet Work?
Semaglutide is a GLP-1 receptor agonist, which means it mimics a natural hormone your body produces after eating. This hormone works by stimulating insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite.
The Wegovy® pill is taken once a day, first thing in the morning on an empty stomach. It’s typically swallowed with a small sip of water (no more than 4 ounces). Then, it’s usually recommended to wait at least 30 minutes before you eat, drink, or take any other medications
Dosing typically starts at 1.5 mg and increases every 30 days until the maintenance dose of 25 mg is reached. This gradual escalation gives your body time to adjust and helps minimize side effects along the way.
Wegovy® Pill Results From the Oasis 4 Clinical Trial
The primary data behind the Wegovy® pill comes from the OASIS 4 clinical trial, which enrolled 307 adults over 64 weeks. Participants took either 25 mg of oral semaglutide or a placebo daily, alongside lifestyle modifications including increased physical activity and a reduced-calorie diet.
In the OASIS 4 clinical trial, participants taking the Wegovy® tablet lost an average of 13.6% of their body weight, compared to 2.2% with the placebo. Individual results, however, may vary. Among participants who remained on treatment for the full trial, average weight loss reached 16.6%.
In the trial, about 30% of participants lost 20% or more of their body weight (34.4% among those who completed treatment), though individual outcomes differed.
Beyond the scale, the trial also showed changes in cardiometabolic health. Over 70% of participants with prediabetes at baseline reached normal blood glucose levels by week 64. Participants who lost 15% or more of their body weight also experienced an average reduction in systolic blood pressure of 10.1 mmHg in the study.
Wegovy® Before and After: What the Timeline Looks Like
Weight loss with the Wegovy® pill varies and, if it happens, is typically gradual. Some people notice changes within the first few weeks of treatment, but the full effect builds over months as the dose increases.
During the initial escalation period (the first several months), you’re working your way up to the 25 mg maintenance dose. This is when your body is adjusting, and results may be modest.
For reference, in the OASIS 4 trial, results were measured at the 64-week mark (roughly 15 months).
Wegovy® Pill vs. Wegovy® Injection: What’s the Difference?
The biggest difference between the two is how you take them. The pill is taken each day orally, but the injection is administered weekly. However, cross-trial comparisons between the OASIS 4 (oral) and STEP 1 (injectable) studies are limited and should be interpreted cautiously, as study designs and patient populations differ.
Yet, there are a few practical differences worth noting. The Wegovy® tablet doesn’t require needles or refrigeration, which makes it simpler to store and travel with. On the other hand, the daily dosing routine is stricter; you’ll need to commit to that empty-stomach, 30-minute-wait protocol every morning.
If you’re currently on injectable Wegovy® and want to switch, it’s possible with provider guidance. The general approach is to start the pill one week after your last injection dose.
Side Effects of the Wegovy® Pill
The side-effect profile is similar to that reported with injectable Wegovy®. The most common issues are gastrointestinal, including:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
These tend to be most noticeable when you first start the medication and during dose increases.
More serious but rare risks include pancreatitis, acute kidney injury (especially if dehydration occurs from vomiting or diarrhea), and gallbladder issues. If you experience severe abdominal pain that doesn’t go away, contact your healthcare provider right away.
The Wegovy® tablet is also not recommended for anyone with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, or severe gastroparesis. It should also be discontinued at least two months before attempting pregnancy.
Is the Wegovy® Pill Right for You?
The Wegovy® tablet may be a good fit if you meet the BMI criteria, prefer a daily oral medication over weekly injections, and can commit to the morning dosing routine.
However, choosing the right medication and determining whether it’s appropriate for your situation is best done with a licensed healthcare provider who understands your full health picture. Wegovy®, pill or injectable form, is only available by prescription.
At Eden, the entire process starts with a quick online intake. To be clear, Eden coordinates your care, but licensed providers evaluate and prescribe, and licensed pharmacies dispense any medications. After your initial intake, Eden connects you with a licensed provider who reviews your health history, goals, and lifestyle to determine which treatment path is right for you. If medication is deemed appropriate, your prescription ships directly to your door from a licensed pharmacy.


The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by state-licensed pharmacies. Please consult a licensed healthcare provider before making any medical decisions.
Frequently asked questions
This varies from person to person. Some people begin noticing changes within the first few weeks, and others notice changes within several months as the dose increases. In clinical trials, outcomes were measured at 64 weeks.
Both oral and injectable Wegovy® have been studied for weight management, though results may vary between individuals and formulations.
The most common side effects are nausea, vomiting, diarrhea, constipation, and abdominal pain. These are usually mild to moderate and tend to ease over time.
The tablet contains an absorption enhancer that works effectively only when taken without food. Eating or drinking too soon may reduce how much medication your body absorbs.
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, obesity & metabolism, 25(1), 18–35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10092086/
NOVO NORDISK INC. (2025b, November 6). Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors. PR NewsWire. https://www.prnewswire.com/news-releases/novo-nordisk-presents-four-new-analyses-on-oral-semaglutide-25-mg-wegovy-in-a-pill-at-obesityweek-2025-including-demonstrated-reductions-in-cardiovascular-risk-factors-302605329.html
Wegovy® Pill Guide and Dosing Information | Wegovy® (semaglutide). (n.d.). https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pill.html
WEGOVY. (2017). WEGOVY (semaglutide) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., Garvey, W. T., & OASIS 4 Study Group (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England journal of medicine, 393(11), 1077–1087. https://pubmed.ncbi.nlm.nih.gov/40934115/
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Thank you!
We'll be in touch.
Thank you!









